|
|
|
|
Anthracycline
|
| |
|
| |
Anthracyclines (or anthracycline antibiotics) are a class of drugs used in cancer chemotherapy derived from Streptomyces bacteria (more specifically, Streptomyces peucetius var. caesius).
These compounds are used to treat a wide range of cancers, including leukemias, lymphomas, and breast, uterine, ovarian, and lung cancers.
The anthracyclines are some of the most effective anticancer treatments ever developed, and are effective against more types of cancer than any other class of chemotherapy agents.

Discussion
Ask a question about 'Anthracycline'
Start a new discussion about 'Anthracycline'
Answer questions from other users
|
Encyclopedia
Anthracyclines (or anthracycline antibiotics) are a class of drugs used in cancer chemotherapy derived from Streptomyces bacteria (more specifically, Streptomyces peucetius var. caesius).
These compounds are used to treat a wide range of cancers, including leukemias, lymphomas, and breast, uterine, ovarian, and lung cancers.
The anthracyclines are some of the most effective anticancer treatments ever developed, and are effective against more types of cancer than any other class of chemotherapy agents. Their main adverse effects are heart damage (cardiotoxicity), which considerably limits their usefulness, and vomiting.
The first anthracycline discovered was daunorubicin (trade name Daunomycin), which is produced naturally by Streptomyces peucetius, a species of actinobacteria. Doxorubicin (Adriamycin) was developed shortly after, and many other related compounds have followed, although few are in clinical use.
Examples
Available agents include:
Since they are antibiotics, anthracyclines can kill or inhibit the growth of bacteria, but because they are so toxic to humans, they are never used to treat infections.
Mechanism of action Anthracycline has three mechanisms of action:
- Inhibits DNA and RNA synthesis by intercalating between base pairs of the DNA/RNA strand, thus preventing the replication of rapidly-growing cancer cells.
- Inhibits topoiosomerase II enzyme, preventing the relaxing of supercoiled DNA and thus blocking DNA transcription and replication.
- Creates iron-mediated free oxygen radicals that damage the DNA and cell membranes.
Cardiotoxicity
As well as many of the expected adverse reactions of chemotherapeutic agents, anthracyclines are notorious for causing cardiotoxicity. This cardiotoxicity may be caused by many factors, which may include interference with the ryanodine receptors of the sarcoplasmic reticulum in the heart muscle cells, free radical formation in the heart or from buildup of metabolic products of the anthracycline in the heart. The cardiotoxicity often presents as EKG changes and arrhythmias, or as a cardiomyopathy leading to congestive heart failure (sometimes presenting many years after treatment). This cardiotoxicity is related to a patient's cumulative lifetime dose. A patient's lifetime dose is calculated during treatment, and anthracycline treatment is usually stopped (or at least re-evaluated by the oncologist) upon reaching the maximum cumulative dose of the particular anthracycline.
There exists evidence that the affect of cardiotoxicity increases in long term survivors, from 2% after 2 years to 5% after 15 years.
Dexrazoxane is a cardioprotectant that is sometimes used to reduce the risk of cardiotoxicity; it has been found to reduce the risk of anthracycline cardiotoxicity by about two thirds, without affecting response to chemotherapy or overall survival. The liposomal formulations of daunorubicin and doxorubicin appear to be somewhat less toxic to cardiac tissue than the non-liposomal form.
See also
|
| |
|
|